Goldman Sachs Group Inc Summit Therapeutics Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 572,791 shares of SMMT stock, worth $16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
572,791
Previous 572,791 -0.0%
Holding current value
$16 Million
Previous $11 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 16, 2025
SELL
$16.65 - $23.76 $651,015 - $929,016
-39,100 Reduced 6.39%
572,791 $11 Million
Q1 2025

May 09, 2025
SELL
$16.65 - $23.76 $4.96 Million - $7.08 Million
-298,111 Reduced 32.76%
611,891 $11.8 Million
Q4 2024

Feb 11, 2025
BUY
$17.52 - $23.46 $7.26 Million - $9.73 Million
414,647 Added 83.71%
910,002 $16.2 Million
Q3 2024

Nov 14, 2024
BUY
$6.89 - $31.93 $285,321 - $1.32 Million
41,411 Added 9.12%
495,355 $10.8 Million
Q2 2024

Aug 13, 2024
SELL
$2.39 - $10.92 $541,710 - $2.48 Million
-226,657 Reduced 33.3%
453,944 $3.54 Million
Q1 2024

May 15, 2024
BUY
$2.55 - $5.07 $1.24 Million - $2.46 Million
486,193 Added 250.09%
680,601 $2.82 Million
Q4 2023

Feb 13, 2024
BUY
$1.67 - $2.83 $3,690 - $6,254
2,210 Added 1.15%
194,408 $507,000
Q3 2023

May 14, 2024
SELL
$1.54 - $2.42 $3,403 - $5,348
-2,210 Reduced 1.14%
192,198 $359,000
Q3 2023

Nov 14, 2023
SELL
$1.54 - $2.42 $244,558 - $384,305
-158,804 Reduced 45.24%
192,198 $359,000
Q2 2023

May 14, 2024
SELL
$1.32 - $2.81 $118,650 - $252,582
-89,887 Reduced 20.39%
351,002 $881,000
Q2 2023

Aug 14, 2023
SELL
$1.32 - $2.81 $118,650 - $252,582
-89,887 Reduced 20.39%
351,002 $881,000
Q1 2023

May 14, 2024
BUY
$1.38 - $5.41 $531,821 - $2.08 Million
385,378 Added 694.24%
440,889 $771,000
Q1 2023

May 11, 2023
BUY
$1.38 - $5.41 $531,821 - $2.08 Million
385,378 Added 694.24%
440,889 $771,000
Q4 2022

May 14, 2024
SELL
$0.68 - $5.31 $3,555 - $27,765
-5,229 Reduced 8.61%
55,511 $235,000
Q4 2022

Feb 13, 2023
SELL
$0.68 - $5.31 $3,555 - $27,765
-5,229 Reduced 8.61%
55,511 $235,000
Q3 2022

May 14, 2024
BUY
$0.89 - $1.63 $23,448 - $42,945
26,347 Added 76.61%
60,740 $72,000
Q3 2022

Nov 10, 2022
BUY
$0.89 - $1.63 $23,448 - $42,945
26,347 Added 76.61%
60,740 $0
Q2 2022

May 14, 2024
SELL
$0.92 - $2.38 $147,213 - $380,835
-160,015 Reduced 82.31%
34,393 $34,000
Q2 2022

Aug 15, 2022
SELL
$0.92 - $2.38 $2,193 - $5,673
-2,384 Reduced 6.48%
34,393 $34,000
Q1 2022

May 16, 2022
SELL
$2.0 - $3.45 $20,626 - $35,579
-10,313 Reduced 21.9%
36,777 $90,000
Q4 2021

Feb 14, 2022
BUY
$2.45 - $5.64 $13,563 - $31,223
5,536 Added 13.32%
47,090 $126,000
Q3 2021

Nov 10, 2021
BUY
$4.83 - $8.27 $200,705 - $343,651
41,554 New
41,554 $208,000

Others Institutions Holding SMMT

# of Institutions
239
Shares Held
88M
Call Options Held
1.84M
Put Options Held
3.13M
View Full List

About Summit Therapeutics Inc.

SMMT Quotes by TradingView
  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $5.61B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email